This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.10.073v1 49/12/1251    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (26) Citing Articles via Google Scholar Google Scholar Articles by Ashrafian, H. Articles by Watkins, H. Search for Related Content PubMed PubMed Citation Articles by Ashrafian, H. Articles by Watkins, H.

CARDIOVASCULAR GENOMIC MEDICINE

Reviews of Translational Medicine and Genomics in Cardiovascular Disease: New Disease Taxonomy and Therapeutic Implications

Cardiomyopathies: Therapeutics Based on Molecular Phenotype

Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, United Kingdom.

Manuscript received July 17, 2006; revised manuscript received October 24, 2006, accepted October 30, 2006.

^_* Reprint requests and correspondence: Prof. Hugh Watkins, Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, Oxfordshire, United Kingdom. (Email: hugh.watkins{at}cardiov.ox.ac.uk).

The enduring subdivision of cardiomyopathies into hypertrophic (HCM), dilated (DCM), and restrictive (RCM) categories reflects the emphasis of traditional classifications on morphology. Rapid advances in the genetic interrogation of these disorders have redefined their taxonomy and revealed potential conflicts between the old and new classifications. Hypertrophic cardiomyopathy has been redefined as a disease of perturbed sarcomere function. Dilated cardiomyopathy is a disease that results from more varied perturbations, including, but not limited to, defects of the cytoskeleton. Positional cloning and candidate gene approaches have been successful in identifying >40 disease loci, many of which have led to disease genes in HCM, DCM, RCM, and arrhythmogenic right ventricular cardiomyopathy. These findings provide mechanistic insights, permit genetic screening, and to a limited extent, facilitate prognostication. Although single gene analyses rapidly focus down to the underlying mechanistic pathways, they do not take account of all relevant variation in the human genome. Correspondingly, advances in genomics, through microarrays, have facilitated characterization of these broader downstream elements. As well as refining the taxonomic reclassification of cardiomyopathies, these genomic approaches, coupled with functional studies, have identified novel potential therapeutic targets, such as cardiac energetics, calcium handling, and apoptosis. We review the successes and pitfalls of genetic and genomic approaches to cardiomyopathy and their impact on current and future clinical care.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   ARVC = arrhythmogenic right ventricular cardiomyopathy   DCM = dilated cardiomyopathy   HCM = hypertrophic cardiomyopathy   LVAD = left ventricular assist device   LVH = left ventricular hypertrophy   MHC = myosin heavy chain   MLP = muscle LIM protein   RCM = restrictive cardiomyopathy   SCD = sudden cardiac death   SNP = single-nucleotide polymorphism

This article has been cited by other articles:

				R. E. Hershberger, J. Cowan, A. Morales, and J. D. Siegfried Progress With Genetic Cardiomyopathies: Screening, Counseling, and Testing in Dilated, Hypertrophic, and Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Circ Heart Fail, May 1, 2009; 2(3): 253 - 261. [Abstract] [Full Text] [PDF]

				R. Formigari, G. Michielon, M. C. Digilio, G. Piacentini, A. Carotti, A. Giardini, R. M. Di Donato, and B. Marino Genetic syndromes and congenital heart defects: how is surgical management affected? Eur. J. Cardiothorac. Surg., April 1, 2009; 35(4): 606 - 614. [Abstract] [Full Text] [PDF]

				S. J. van Dijk, D. Dooijes, C. dos Remedios, M. Michels, J. M.J. Lamers, S. Winegrad, S. Schlossarek, L. Carrier, F. J. ten Cate, G. J.M. Stienen, et al. Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction Circulation, March 24, 2009; 119(11): 1473 - 1483. [Abstract] [Full Text] [PDF]

				C. A. Piantadosi, M. S. Carraway, A. Babiker, and H. B. Suliman Heme Oxygenase-1 Regulates Cardiac Mitochondrial Biogenesis via Nrf2-Mediated Transcriptional Control of Nuclear Respiratory Factor-1 Circ. Res., November 21, 2008; 103(11): 1232 - 1240. [Abstract] [Full Text] [PDF]

				H. Ashrafian and H. Watkins Exercise-induced ventricular dysfunction in hypertrophic cardiomyopathy: stunning by any other name? Heart, October 1, 2008; 94(10): 1251 - 1253. [Full Text] [PDF]

				H Watkins, H Ashrafian, and W J McKenna The genetics of hypertrophic cardiomyopathy: Teare redux Heart, October 1, 2008; 94(10): 1264 - 1268. [Full Text] [PDF]

				S. Yamada, T. J. Nelson, R. J. Crespo-Diaz, C. Perez-Terzic, X.-K. Liu, T. Miki, S. Seino, A. Behfar, and A. Terzic Embryonic Stem Cell Therapy of Heart Failure in Genetic Cardiomyopathy Stem Cells, October 1, 2008; 26(10): 2644 - 2653. [Abstract] [Full Text] [PDF]

				A. M. Jacques, N. Briceno, A. E. Messer, C. E. Gallon, S. Jalilzadeh, E. Garcia, G. Kikonda-Kanda, J. Goddard, S. E. Harding, H. Watkins, et al. The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy Cardiovasc Res, August 1, 2008; 79(3): 481 - 491. [Abstract] [Full Text] [PDF]

				T. Koyanagi, L. Y. Wong, K. Inagaki, O. V. Petrauskene, and D. Mochly-Rosen Alteration of gene expression during progression of hypertension-induced cardiac dysfunction in rats Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H220 - H226. [Abstract] [Full Text] [PDF]

				I. Olivotto, F. Girolami, M. J. Ackerman, S. Nistri, J. M. Bos, E. Zachara, S. R. Ommen, J. L. Theis, R. A. Vaubel, F. Re, et al. Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy Mayo Clin. Proc., June 1, 2008; 83(6): 630 - 638. [Abstract] [Full Text] [PDF]

				S. Waldmuller, M. Muller, K. Rackebrandt, P. Binner, S. Poths, M. Bonin, and T. Scheffold Array-Based Resequencing Assay for Mutations Causing Hypertrophic Cardiomyopathy Clin. Chem., April 1, 2008; 54(4): 682 - 687. [Abstract] [Full Text] [PDF]

				S. Yacoub, A. O. Mocumbi, and M. H Yacoub Neglected tropical cardiomyopathies: I. Chagas disease Heart, February 1, 2008; 94(2): 244 - 248. [Full Text] [PDF]

				G. Thiene, D. Corrado, and C. Basso Revisiting definition and classification of cardiomyopathies in the era of molecular medicine Eur. Heart J., January 2, 2008; 29(2): 144 - 146. [Full Text] [PDF]

				P. Robinson, P. J. Griffiths, H. Watkins, and C. S. Redwood Dilated and Hypertrophic Cardiomyopathy Mutations in Troponin and {alpha}-Tropomyosin Have Opposing Effects on the Calcium Affinity of Cardiac Thin Filaments Circ. Res., December 7, 2007; 101(12): 1266 - 1273. [Abstract] [Full Text] [PDF]

				R. J. Solaro Translational Medicine With a Capital T, Troponin T, That Is Circ. Res., July 20, 2007; 101(2): 114 - 115. [Full Text] [PDF]